Hydrochlorothiazide

CHEMBL435 Phase 4 Disetujui Small molecule
Half-Life
6-15 hours
Bioavailability
Protein Binding
Molecular Weight
297.7 g/mol
LogP
-0.1
Phase
4

A thiazide diuretic that lowers blood pressure by reducing fluid volume through increased urine output and by relaxing blood vessels, widely used alone or in combination with other antihypertensives to treat high blood pressure, heart failure, and edema. It is also used to prevent kidney stones in patients with high urinary calcium. Potassium levels should be monitored as this medication can cause hypokalemia.

Berat Molekul

297,7400 g/mol

LogP

-0,10

TPSA

135,00 Ų

Lipinski RO5

Lulus

Area Terapeutik

Kelas Obat

Mekanisme Kerja

Inhibits Na+/Cl- cotransporter in distal convoluted tubule.

Pharmacokinetics (PK)

Half-Life 6-15 hours

Pharmacodynamics (PD)

Mekanisme

Inhibits Na+/Cl- cotransporter in distal convoluted tubule.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O

InChI

InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

Molecular Formula

C7H8ClN3O4S2

HBD / HBA

3 / 7

Ikatan yang Dapat Dirotasi

1

Atom Berat

17

Primary Target
Major Hydrochlorothiazide + Lithium Carbonate

Thiazide diuretics increase lithium reabsorption in the proximal renal tubule, reliably causing lithium toxicity without dose adjustment.

Minor Hydrochlorothiazide + Lisinopril

The ACE inhibitor and thiazide combination is guideline-recommended for hypertension but can cause first-dose hypotension and metabolic disturbances including hypokalemia or hyperkalemia.

Minor Hydrochlorothiazide + Losartan

Losartan + hydrochlorothiazide is a guideline-recommended combination for hypertension; the primary interactions are additive hypotension and variable electrolyte effects.

Minor Hydrochlorothiazide + Memantine

Hydrochlorothiazide may reduce renal clearance of memantine through alkalinisation of urine, as memantine elimination is pH-dependent; the clinical impact is generally minor.

Moderate Hydrochlorothiazide + Naproxen

Naproxen reduces the diuretic and antihypertensive efficacy of thiazide diuretics, blunting blood pressure control.

Minor Hydrochlorothiazide + Gabapentin

Hydrochlorothiazide-induced sodium and fluid loss can increase the risk of dizziness and orthostatic hypotension when combined with gabapentin, which also causes dizziness and impairs balance.

Moderate Hydrochlorothiazide + Furosemide

Sequential nephron blockade with furosemide and thiazide diuretics produces a synergistic diuretic effect that can rapidly cause severe hypovolemia, hyponatremia, and hypokalemia.

Moderate Hydrochlorothiazide + Empagliflozin

The combination of empagliflozin and hydrochlorothiazide can cause additive volume depletion and hypotension, and may also increase the risk of genital mycotic infections through shared glucosuria.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A thiazide diuretic that lowers blood pressure by reducing fluid volume through increased urine output and by relaxing blood vessels, widely used alone or in combination with other antihypertensives to treat high blood pressure, heart failure, and edema. It is also used to prevent kidney stones in patients with high urinary calcium. Potassium levels should be monitored as this medication can cause hypokalemia.

Inhibits Na+/Cl- cotransporter in distal convoluted tubule.

Key pharmacokinetic parameters for Hydrochlorothiazide: Half-life: 6-15 hours.

Yes, Hydrochlorothiazide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL435. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3639. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.